Shots:
- The EC has approved Uplizna (inebilizumab) as an add-on treatment of anti-AChR & anti-MuSK antibody positive adults with gMG
- Approval was based on P-III (MINT) trial in 238 adults with gMG (190 AChR+, 48 MuSK+), where pts received 2 Uplizna loading doses followed by 2 doses/year
- Pts on steroids began tapering at Wk. 4, reducing to prednisone (5mg/day) by Wk. 24 & by Wk. 26, 87.4% on Uplizna vs 84.6% on PBO achieved ≤5 mg/day
Ref: PRnewswire | Image: Amgen | Press Release
Related News: Amgen Acquires Dark Blue Therapeutics for ~$840M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
